When is Prostate Cancer Really Cancer?

被引：41

作者：

Berman, David M.

Epstein, Jonathan I.

机构：

[1] Department of Pathology and Molecular Medicine, Queen's Cancer Research Institute, Queen's University, Kingston, ON K7L3N6, 18 Stuart Street

[2] Departments of Pathology, Urology, and Oncology, The Johns Hopkins Medical Institutions, Baltimore, MD 21231

来源：

UROLOGIC CLINICS OF NORTH AMERICA | 2014年 / 41卷 / 02期

关键词：

COA RACEMASE P504S; RADICAL PROSTATECTOMY; HIGH-GRADE; INTRAEPITHELIAL NEOPLASIA; BASEMENT-MEMBRANE; 8P SEQUENCES; GLEASON; ADENOCARCINOMA; HALLMARKS; EXPRESSION;

D O I：

10.1016/j.ucl.2014.01.006

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

100201 [内科学]; 100221 [泌尿外科学];

摘要：

Several investigators have challenged the idea that low-grade cancers are a cause for concern, suggesting that the term cancer should not be applied to these tumors. This article reviews the defining features of cancer, and the diagnostic and prognostic classification systems currently used for prostate cancer. Logical, morphologic, and molecular evidence is presented to show that low-grade prostate cancers are correctly classified as cancer. The authors suggest, however, that 6 out of 10 on an aggressiveness scale is inappropriate for indolent cancer, and that a proposed reinterpretation of Gleason grading categories is a more logical way to address overtreatment.

引用

页码：339 / 346

页数：8

共 51 条

[1]

Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy? [J].

Ahmed, Hashim Uddin ;

Arya, Manit ;

Freeman, Alex ;

Emberton, Mark .

LANCET ONCOLOGY, 2012, 13 (11) :E509-E517

[2]

Low Gleason score prostatic adenocarcinomas are no longer viable entities [J].

Berney, D. M. .

HISTOPATHOLOGY, 2007, 50 (06) :683-690

[3]

PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer [J].

Bismar, Tarek A. ;

Yoshimoto, Maisa ;

Vollmer, Robin T. ;

Duan, Qiuli ;

Firszt, Matthew ;

Corcos, Jacques ;

Squire, Jeremy A. .

BJU INTERNATIONAL, 2011, 107 (03) :477-485

[4]

DISTRIBUTION OF BASEMENT-MEMBRANES IN PRIMARY AND METASTATIC CARCINOMAS OF THE PROSTATE [J].

BONKHOFF, H ;

WERNERT, N ;

DHOM, G ;

REMBERGER, K .

HUMAN PATHOLOGY, 1992, 23 (08) :934-939

[5]

BOSTWICK DG, 1995, PATHOL RES PRACT, V191, P850, DOI 10.1016/S0344-0338(11)80967-2

[6]

Gleason Score 6 Adenocarcinoma: Should It Be Labeled As Cancer? [J].

Carter, H. Ballentine ;

Partin, Alan W. ;

Walsh, Patrick C. ;

Trock, Bruce J. ;

Veltri, Robert W. ;

Nelson, William G. ;

Coffey, Donald S. ;

Singer, Eric A. ;

Epstein, Jonathan I. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (35) :4294-4296

[7]

Tumorigenic potential of circulating prostate tumor cells [J].

Carvalho, Filipe L. F. ;

Simons, Brian W. ;

Antonarakis, Emmanuel S. ;

Rasheed, Zeshaan ;

Douglas, Nora ;

Villegas, Daniela ;

Matsui, William ;

Berman, David M. .

ONCOTARGET, 2013, 4 (03) :413-421

[8]

Cheng L, 1999, CANCER-AM CANCER SOC, V86, P657, DOI 10.1002/(SICI)1097-0142(19990815)86:4<657::AID-CNCR15>3.3.CO

[9]

2-0

[10]

Epidemiology of basal cell carcinoma [J].

Chinem, Valquiria Pessoa ;

Miot, Helio Amante .

ANAIS BRASILEIROS DE DERMATOLOGIA, 2011, 86 (02) :292-305

← 1 2 3 4 5 6 →